Compare LGVN & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGVN | JTAI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 8.1M |
| IPO Year | 2021 | N/A |
| Metric | LGVN | JTAI |
|---|---|---|
| Price | $0.62 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $80.00 |
| AVG Volume (30 Days) | ★ 278.7K | 111.4K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | $0.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.04 |
| 52 Week High | $1.80 | $10.41 |
| Indicator | LGVN | JTAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.16 | 22.38 |
| Support Level | $0.50 | $1.46 |
| Resistance Level | $0.68 | $8.02 |
| Average True Range (ATR) | 0.05 | 0.82 |
| MACD | -0.00 | -0.49 |
| Stochastic Oscillator | 8.05 | 1.46 |
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Jet AI Inc is principally involved in the sale of fractional and whole interests in aircraft, the sale of jet cards, which enable holders to use certain of the company's and other's aircraft at agreed-upon rates, the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the company's leased and managed aircraft, direct chartering of its HondaJet Elite aircraft by Cirrus Aviation Services, aircraft brokerage and monthly management and hourly operation of customer aircraft. It also offers the SaaS software to aircraft owners and operators generally: Reroute AI; and DynoFlight. The company operates in a single operating and reportable segment which is private aviation services.